1548.HK Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 май 2024 @ 11:08):

Stats
Объем за сегодня	5.89M
Средний объем	12.27M
Рыночная капитализация	25.22B
EPS	HKD0 ( 2024-03-29 )
Дата следующего отчета о доходах	( HKD0 ) 2024-05-17
Last Dividend	HKD0.0120 ( 2017-06-05 )
Next Dividend	HKD0 ( N/A )
P/E	-34.29
ATR14	HKD0.0100 (0.08%)

Объем Корреляция

Длинно: -0.32 (neutral)

Кратко: 0.22 (neutral)

Signal:(51.459) Neutral

Genscript Biotech Corp Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Genscript Biotech Corp Корреляция - Валюта/Сырье

0.06
( neutral )

-0.22
( neutral )

0.00
( neutral )

-0.07
( neutral )

0.71
( moderate )

0.11
( neutral )

Genscript Biotech Corp Финансовые показатели

Annual	2023
Выручка:	HKD839.53M
Валовая прибыль:	HKD409.55M (48.78 %)
EPS:	HKD-0.0453

FY	2023
Выручка:	HKD839.53M
Валовая прибыль:	HKD409.55M (48.78 %)
EPS:	HKD-0.0453

FY	2022
Выручка:	HKD625.70M
Валовая прибыль:	HKD304.08M (48.60 %)
EPS:	HKD-0.110

FY	2021
Выручка:	HKD510.60M
Валовая прибыль:	HKD303.02M (59.35 %)
EPS:	HKD-0.171

Financial Reports:

No articles found.

Genscript Biotech Corp Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Genscript Biotech Corp Dividend Information - No Dividend Player

Dividend Sustainability Score: 2.51 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	HKD0.0120	2017-06-05
Last Dividend	HKD0.0120	2017-06-05
Next Dividend	HKD0	N/A
Payout Date	2017-06-21
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	HKD0.0120	--
Avg. Dividend % Per Year	0.00%	--
Score	0.29	--
Div. Sustainability Score	2.51
Div.Growth Potential Score	0
Div. Directional Score	0.922	--

Next Divdend (Est)
(2024-05-04)

HKD0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.29

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2588.HK	Ex Dividend Knight	2023-09-25	Semi-Annually	0.00%
1381.HK	Ex Dividend Knight	2023-09-11	Semi-Annually	0.00%
0440.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
6826.HK	Ex Dividend Knight	2023-07-04	Annually	0.00%
1931.HK	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
0960.HK	Ex Dividend Knight	2023-12-29	Semi-Annually	0.00%
0083.HK	Ex Dividend Knight	2023-10-27	Semi-Annually	0.00%
3316.HK	Ex Dividend Knight	2023-06-20	Annually	0.00%
1525.HK	Ex Dividend Knight	2023-06-13	Semi-Annually	0.00%
0573.HK	Ex Dividend Knight	2023-10-05	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.114	1.500	-2.27	-3.41	[0 - 0.5]
returnOnAssetsTTM	-0.0282	1.200	-0.940	-1.127	[0 - 0.3]
returnOnEquityTTM	-0.0695	1.500	-1.884	-2.83	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.76	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.34	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.92	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.123	-1.500	7.95	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.144	2.00	-0.0480	-0.0959	[0 - 30]
freeCashFlowPerShareTTM	-0.271	2.00	-0.135	-0.271	[0 - 20]
debtEquityRatioTTM	0.300	-1.500	8.80	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.488	1.000	5.20	5.20	[0.2 - 0.8]
operatingProfitMarginTTM	-0.495	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.688	1.000	-4.93	-4.93	[0.2 - 2]
assetTurnoverTTM	0.248	0.800	-1.681	-1.345	[0.5 - 2]
Total Score				2.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-32.08	1.000	-3.34	0	[1 - 100]
returnOnEquityTTM	-0.0695	2.50	-1.211	-2.83	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.271	2.00	-0.0902	-0.271	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.144	2.00	-0.0480	-0.0959	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.27	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.342	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-0.665

Genscript Biotech Corp

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.